ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2149

Rheumatoid Arthritis: Patient’s Voice First! An Original Approach Based on Infodemiology Using Social Media Content – Results from the PRIMA Study

Jérémie Sellam1, Luisa Attali2, Sonia Trope3, Paméla Voillot4 and Cécile Gaujoux-Viala5, 1Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, 2Centre de recherches en médecine, psychanalyse et société - Université Paris, Strasbourg, France, 3ANDAR, Paris, Ile-de-France, France, 4Kap code, Paris, France, 5CHU Nîmes, Nïmes, Languedoc-Roussillon, France

Meeting: ACR Convergence 2024

Keywords: pain, Qualitative Research, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Social media and online forums are popular for understanding patients’ feelings and concerns, which are hard to assess with traditional methods. Infodemiology collects and analyzes health content from social media (1). This study aimed to describe RA patients’ discussions on social media and their perceptions of life with the disease.

Methods: Posts related to RA patients geolocated in France between Jan 2018 and Dec 2019 (to avoid COVID-19 pandemic influence) were mainly extracted from 10 general and specialized, publicly available online forums. The extracted messages were cleaned and anonymized. Automated language processing methods were used to analyze patients’ verbatim comments. We used MedDRA and a Biterm Topic Model (BTM) algorithm to identify and analyze discussed topics. We used qualitative methods to describe issues patients raised about the impact of the disease on their quality of life (QoL).

Results: The extraction yielded 9,326 posts. After curation, 6,029 posts from 3,772 patients were included and analyzed. Patients’ data mostly came from the patient association blog ParlonsdelaPR (41%), X (exTwitter) (21%) and Doctissimo health forum (11%). Posts publication did not follow any seasonality.

Sex and age were reported in 77% and 89% of posts, respectively. Among them, 79% (2,300/2,904) were women and the median age was 41 years-old (range 19-61).

Among these 6,029 posts, the top 3 topics of patients’ discussions were daily pain (27%; considering and managing pain), finding community support (20%; seeking information on RA and treatments, empathy and encouragement) and personal testimonies (17%; medical history and wandering, disease acceptation, living and coping with RA, self-management).

The impact on QoL was mentioned by 54% (2,052/3,772) of the posts. Of these, 76% described physical health effects (e.g.: pain, fatigue, weight gain), then psychological effects (51%; e.g.: stress, anxiety, depressive mood, fear of the disease, risk of disability and changes in physical appearance) and limitation in physical and social activities (40%; e.g.: mobility, sport, work). For some patients experiencing difficulties, the publication of negative contributions could be counterproductive.

One-third of posts (1,077/3,772) mentioned their overall care and the difficulty to deal with family and friends as well as caregivers. Of these, 19% provided lifestyle advice (exercise, reducing alcohol, exclusion diet, complementary-alternative medicine) but the benefit of smoking cessation was lacking.

Conclusion: RA patients use social media for coping strategies, support, and information. Despite various treatments, they remain uncertain about their disease and future. Negative messages can reduce their empowerment and motivation. Although patients make lifestyle changes, smoking cessation is often not prioritized. COVID-19 pandemic influence on patients’ contribution in social media will be analyzed through a further pre-and post-COVID-19 periods analysis.


Disclosures: J. Sellam: AbbVie/Abbott, 7, Bristol-Myers Squibb(BMS), 7, Fresenus kabi, 7, Galapagos, 7, Grunenthal, 7, MSD, 7, Nordic Pharma, 7, Novartis, 7, Pfizer, 7; L. Attali: Exeltis, 7, Nordic Pharma, 7; S. Trope: Nordic Pharma, 7; P. Voillot: Nordic Pharma, 12, Kap code employee (Contract Research Organisation); C. Gaujoux-Viala: AbbVie/Abbott, 2, Alfasigma, 2, Amgen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Celgene, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, Janssen, 2, Medac, 2, Merck-Serono, 2, Mylan, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Roche, 2, Sandoz, 2, Sanofi, 2, UCB, 2, Viatrix, 2.

To cite this abstract in AMA style:

Sellam J, Attali L, Trope S, Voillot P, Gaujoux-Viala C. Rheumatoid Arthritis: Patient’s Voice First! An Original Approach Based on Infodemiology Using Social Media Content – Results from the PRIMA Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-patients-voice-first-an-original-approach-based-on-infodemiology-using-social-media-content-results-from-the-prima-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-patients-voice-first-an-original-approach-based-on-infodemiology-using-social-media-content-results-from-the-prima-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology